4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Retrieved on:
Wednesday, January 3, 2024
Biology, Entrepreneurship, Partnership, ALS, Gene editing, Cardiology, A101, Drug development, R100, Protein engineering, FDA, CRISPR, Cystic fibrosis, Disease, Tissue, Brain, PAMS, Vivisection, AAV, Artificial intelligence, DSM-IV codes, Ophthalmology, CNS, Engineering, Machine learning, Genome, Central nervous system, Patient, Therapy, Vaccine
Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
Key Points:
- Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
- 4DMT has utilized its platform to invent customized AAV vectors for CNS tissues, and these vectors will be deployed in the partnership.
- “CNS disorders include some of the most devastating diseases, many of which have a genetic origin.
- We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines.